Relapse Prevention Study in Newly Abstinent Smokers

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to determine the effect of GSK598809 as compared to placebo in preventing recently-quit smokers from going back to smoking.

Clinical Trial Description

The primary objective of this study is to evaluate the efficacy of GSK598809 compared to placebo for the prevention of relapse to smoking in recently abstinent smokers. Subjects who meet eligibility criteria will enter a 4-week open label treatment period during which they will receive nicotine replacement therapy (NRT). Subjects who have achieved at least one week of abstinence during the last week of an open label treatment period will be randomized to either GSK598809 or placebo in the double-blind treatment period and followed for another 12 weeks. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00793468
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Withdrawn
Phase	Phase 2
Start date	December 2008
Completion date	December 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00887367` - EtOH Interaction Study	Phase 1
Completed	`NCT01036061` - GSK618334 Repeat Dose Study	Phase 1
Completed	`NCT01189799` - Motivational Therapy for Substance Users With Depression	N/A
Completed	`NCT01381133` - Adolescent Outpatient and Continuing Care Study	Phase 3
Recruiting	`NCT04430257` - Pre-exposure Prophylaxis (PrEP) for Health	N/A
Completed	`NCT01128140` - Efficacy Trial of Warrior Check-Up	Phase 2
Completed	`NCT03767907` - Online Cognitive Behavioural Therapy for Addiction: Efficacy and Cost-Effectiveness in a Pragmatic Clinical Trial	N/A
Recruiting	`NCT05833399` - Correlation of Genetic Variations With Clinical Response in Substance Use Disorder
Withdrawn	`NCT01515917` - Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)	N/A
Completed	`NCT00208143` - Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia	Phase 4
Withdrawn	`NCT03762798` - Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone	N/A
Completed	`NCT03048552` - Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3	N/A
Active, not recruiting	`NCT04768920` - Examining Feasibility and Acceptability of Telemedicine for Substance Use Disorder (SUD)	N/A
Recruiting	`NCT05410561` - Harnessing Telemedicine to Improve Alcohol Use Disorder Outcomes in Primary Care Patients	N/A
Recruiting	`NCT05679284` - A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs
Withdrawn	`NCT00908206` - Effects of GSK598809 on Brain Activation in Abstinent Alcoholics	Phase 1
Recruiting	`NCT05348317` - Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders	N/A
Recruiting	`NCT01741415` - Distress Tolerance Treatment for Substance Users	Phase 2
Active, not recruiting	`NCT01621711` - Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care	N/A
Active, not recruiting	`NCT00609089` - Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction	Phase 1/Phase 2